Pixantrone–rituximab versus gemcitabine–rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma

View our exclusive infographic, which depicts the rationale and design of the ongoing Phase III PIX306 study. This trial has been designed to evaluate the efficacy of pixantrone and rituximab versus gemcitabine and rituximab in patients with diffuse large B-cell lymphoma or follicular grade 3 lymphoma.

The associated Clinical Trial Protocol paper from Future Oncology can be accessed here.